Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lizotte, Patrick H ^a,b   Jones, Robert E ^a,b   Keogh, Lauren ^a,b   Ivanova, Elena ^a,b   Liu, Hongye ^a,b   Awad, Mark M ^b,c   Hammerman, Peter S ^b,c   Gill, Ritu R ^b,d   Richards, William G ^c,d   Barbie, David A ^b,c   Bass, Adam J ^b,c   Bueno, Raphael ^c,d   English, Jessie M ^a,b   Bittinger, Mark ^a,b   Wong, Kwok Kin ^a,b,c  

^a Belfer Institute for Innovative Cancer Science   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FLOW CYTOMETRY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MALE; MESOTHELIOMA; PATHOLOGY; T LYMPHOCYTE; THORAX TUMOR; TUMOR MICROENVIRONMENT;

BIOPSY, FINE-NEEDLE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNE TOLERANCE; MALE; MESOTHELIOMA; T-LYMPHOCYTES; THORACIC NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84983371513     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31745     Document Type: Article

References (26)

1. Brahmer, J. R. et al. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
2. Goding, S. R. et al. Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma. J. Immunol. 190, 4899-4909 (2013).
3. Hodi, F. S. et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N. Engl. J. Med. 363, 711-723 (2010).
4. Liu, J. et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc. Natl. Acad. Sci. 112, 6682-6687 (2015).
5. Topalian, S. L. et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
6. Lu, L. et al. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J. Transl. Med. 12, 36 (2014).
7. Sanmamed, M. F. et al. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin. Oncol. 42, 640-655 (2015).
8. Boyd, J. D., Smith, G. D., Hong, H., Mageau, R. & Juskevicius, R. Fine-Needle Aspiration is Superior to Needle Core Biopsy as a Sample Aquisition Method for Flow Cytometric Analysis in Suspected Hematologic Neoplasms. Cytometry B Clin. Cytom (2014).
9. Demurtas, A. et al. Utility of flow cytometry immunophenotyping in fine-needle aspirate cytologic diagnosis of non-Hodgkin lymphoma: A series of 252 cases and review of the literature. Appl. Immunohistochem. Mol. Morphol. AIMM Off. Publ. Soc. Appl. Immunohistochem. 18, 311-322 (2010).
10. Factor, R. & Layfield, L. J. Intraprocedural evaluation of fine-needle aspiration smears: how good are we? Diagn. Cytopathol. 40, 760-763 (2012).
11. Gupta, R., Naseem, S., Kashyap, R. & Paul, L. Role of fine-needle aspirate immunophenotyping by flow cytometry in rapid diagnosis of lymphoproliferative disorders. Diagn. Cytopathol. 35, 381-385 (2007).
12. Hehn, S. T., Grogan, T. M. & Miller, T. P. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 22, 3046-3052 (2004).
13. Austin, R. M. et al. Fine Needle Aspiration Is a Feasible and Accurate Technique in the Diagnosis of Lymphoma. J. Clin. Oncol. 23, 9029-9030 (2005).
14. Grosso, J. et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). ASCO Meet. Abstr. 31, 3016 (2013).
15. Ji, R.-R. et al. An immune-Active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. CII 61, 1019-1031 (2012).
16. Kwek, S. S. et al. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol. Res. 3, 1008-1016 (2015).
17. Santegoets, S. J. et al. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J. Immunother. Cancer 2, 31 (2014).
18. Santegoets, S. J. A. M. et al. T cell profiling reveals high CD4+ CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol. Immunother. CII 62, 245-256 (2013).
19. Spranger, S. et al. Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells. Sci. Transl. Med. 5, 200ra116 (2013).
20. Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226ra32 (2014).
21. Bodenmiller, B. et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat. Biotechnol. 30, 858-867 (2012).
22. Borghaei, H. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 373, 1627-1639 (2015).
23. Patnaik, A. et al. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 21, 4286-4293 (2015).
24. Murtagh, F. Multidimensional Clustering Algorithms. (Wuerzburg: Physica-Verlag, 1985).
25. Murtagh, F. & Legendre, P. Wards Hierarchical Agglomerative Clustering Method: Which Algorithms Implement Wards Criterion?-Springer. J. Classif. 31, 274-295 (2014).
26. Van Der Maaten, L. Accelerating t-SNE Using Tree-based Algorithms. J Mach Learn Res 15, 3221-3245 (2014).